Zealand Pharma A/S (ZLDPF)
USD 63.36
(0.57%)
USD 63.36
(0.57%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 226.92 Million DKK | -2.15% |
| 2022 | 920.58 Million DKK | -24.79% |
| 2021 | 1.22 Billion DKK | 12.13% |
| 2020 | 1.09 Billion DKK | 73.57% |
| 2019 | 628.86 Million DKK | 21.97% |
| 2018 | 515.58 Million DKK | 38.77% |
| 2017 | 371.53 Million DKK | 16.48% |
| 2016 | 318.96 Million DKK | 29.27% |
| 2015 | 246.73 Million DKK | 15.55% |
| 2014 | 213.53 Million DKK | 11.61% |
| 2013 | 191.32 Million DKK | 9.18% |
| 2012 | 175.23 Million DKK | 31.35% |
| 2011 | 133.4 Million DKK | -31.95% |
| 2010 | 196.05 Million DKK | 86.28% |
| 2009 | 105.24 Million DKK | 4.25% |
| 2008 | 100.95 Million DKK | -17.56% |
| 2007 | 122.44 Million DKK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 285.55 Million DKK | 12.55% |
| 2024 Q1 | 259.71 Million DKK | 2.29% |
| 2023 Q1 | 189.36 Million DKK | -27.97% |
| 2023 FY | 900.83 Million DKK | -2.15% |
| 2023 Q4 | 253.89 Million DKK | 2.96% |
| 2023 Q3 | 246.59 Million DKK | 16.88% |
| 2023 Q2 | 210.97 Million DKK | 11.41% |
| 2022 Q4 | 262.9 Million DKK | 28.11% |
| 2022 FY | 920.58 Million DKK | -24.79% |
| 2022 Q3 | 205.21 Million DKK | -22.58% |
| 2022 Q2 | 265.08 Million DKK | 11.57% |
| 2022 Q1 | 237.58 Million DKK | -25.23% |
| 2021 Q4 | 317.75 Million DKK | 9.74% |
| 2021 Q2 | 331.68 Million DKK | 16.39% |
| 2021 FY | 1.22 Billion DKK | 12.13% |
| 2021 Q1 | 284.97 Million DKK | -24.62% |
| 2021 Q3 | 289.53 Million DKK | -12.71% |
| 2020 Q3 | 277.15 Million DKK | 12.34% |
| 2020 Q2 | 246.7 Million DKK | 30.1% |
| 2020 FY | 1.09 Billion DKK | 73.57% |
| 2020 Q1 | 189.62 Million DKK | -3.89% |
| 2020 Q4 | 378.03 Million DKK | 36.4% |
| 2019 FY | 628.86 Million DKK | 21.97% |
| 2019 Q1 | 135.78 Million DKK | 620.82% |
| 2019 Q2 | 156.02 Million DKK | 14.9% |
| 2019 Q3 | 139.75 Million DKK | -10.43% |
| 2019 Q4 | 197.3 Million DKK | 41.18% |
| 2018 Q4 | -26.07 Million DKK | -108.55% |
| 2018 Q2 | 145.02 Million DKK | 57.84% |
| 2018 Q1 | 91.88 Million DKK | -23.32% |
| 2018 FY | 515.58 Million DKK | 38.77% |
| 2018 Q3 | 304.75 Million DKK | 110.14% |
| 2017 Q2 | 104.34 Million DKK | 48.08% |
| 2017 FY | 371.53 Million DKK | 16.48% |
| 2017 Q4 | 119.82 Million DKK | 55.83% |
| 2017 Q3 | 76.89 Million DKK | -26.3% |
| 2017 Q1 | 70.46 Million DKK | -28.17% |
| 2016 Q1 | 70.31 Million DKK | -0.35% |
| 2016 Q4 | 98.09 Million DKK | 76.93% |
| 2016 Q3 | 55.44 Million DKK | -41.7% |
| 2016 Q2 | 95.1 Million DKK | 35.26% |
| 2016 FY | 318.96 Million DKK | 29.27% |
| 2015 Q2 | 70.7 Million DKK | 28.57% |
| 2015 Q4 | 70.55 Million DKK | 39.79% |
| 2015 FY | 246.73 Million DKK | 15.55% |
| 2015 Q1 | 54.99 Million DKK | -25.02% |
| 2015 Q3 | 50.47 Million DKK | -28.62% |
| 2014 Q3 | 43.44 Million DKK | -16.18% |
| 2014 Q4 | 73.35 Million DKK | 68.86% |
| 2014 FY | 213.53 Million DKK | 11.61% |
| 2014 Q1 | 44.91 Million DKK | -6.72% |
| 2014 Q2 | 51.82 Million DKK | 15.38% |
| 2013 FY | 191.32 Million DKK | 9.18% |
| 2013 Q4 | 48.15 Million DKK | 30.12% |
| 2013 Q3 | 37 Million DKK | -23.3% |
| 2013 Q2 | 48.24 Million DKK | -16.69% |
| 2013 Q1 | 57.91 Million DKK | 5.32% |
| 2012 Q2 | 43.45 Million DKK | 10.36% |
| 2012 Q1 | 39.38 Million DKK | -7.61% |
| 2012 FY | 175.23 Million DKK | 31.35% |
| 2012 Q4 | 54.98 Million DKK | 47.0% |
| 2012 Q3 | 37.4 Million DKK | -13.93% |
| 2011 Q2 | 27.58 Million DKK | -36.32% |
| 2011 Q4 | 42.62 Million DKK | 114.33% |
| 2011 Q1 | 43.31 Million DKK | -35.18% |
| 2011 FY | 133.4 Million DKK | -31.95% |
| 2011 Q3 | 19.88 Million DKK | -27.9% |
| 2010 Q1 | 25.67 Million DKK | 0.0% |
| 2010 FY | 196.05 Million DKK | 86.28% |
| 2010 Q2 | 51.4 Million DKK | 100.22% |
| 2010 Q3 | 52.16 Million DKK | 1.47% |
| 2010 Q4 | 66.81 Million DKK | 28.1% |
| 2009 FY | 105.24 Million DKK | 4.25% |
| 2008 FY | 100.95 Million DKK | -17.56% |
| 2007 FY | 122.44 Million DKK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 29.55 Million USD | -667.871% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -4400.734% |
| CSL Limited | 3.44 Billion USD | 93.42% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -509.113% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -24472.446% |
| BioStem Technologies, Inc. | 22.97 Million USD | -887.73% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -1988.24% |
| Qrons Inc. | 643.67 Thousand USD | -35155.105% |
| Nascent Biotech, Inc. | 2.22 Million USD | -10076.741% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -295.071% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -3277.917% |
| Skye Bioscience, Inc. | 13.54 Million USD | -1575.056% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -54518.645% |
| Rebus Holdings, Inc. | 664 Thousand USD | -34076.054% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -1317.399% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -16892.941% |
| Genscript Biotech Corporation | 825.34 Million USD | 72.505% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -58151.747% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -161.484% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -4514.335% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -86604.798% |
| SQZ Biotechnologies Company | 85.61 Million USD | -165.045% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -7681.575% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -15009.471% |
| Mesoblast Limited | 5.9 Million USD | -3744.951% |
| Marizyme, Inc. | 19.23 Million USD | -1079.475% |
| Genus plc | 147.7 Million USD | -53.642% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -2484.838% |
| Pharming Group N.V. | 225.49 Million USD | -0.638% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -10976.705% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -16815.497% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -2621.298% |
| ContraFect Corporation | 56.88 Million USD | -298.898% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -5047.332% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -15245.981% |
| IMV Inc. | 37.7 Million USD | -501.787% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -8032.615% |
| MultiCell Technologies, Inc. | 567.42 USD | -39993026.784% |
| ONE Bio Corp. | 6.44 Million USD | -3421.614% |
| Accustem Sciences Inc. | 3.74 Million USD | -5957.224% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -164.04% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -42558.874% |
| Q BioMed Inc. | 3.43 Million USD | -6503.246% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -818.183% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -8536.617% |
| Biomind Labs Inc. | 994.18 Thousand USD | -22725.7% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -128.459% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -12796.053% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -12071.886% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 907816.0% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -12266.063% |
| GB Sciences, Inc. | 1.42 Million USD | -15875.189% |
| Alpha Cognition Inc. | 9.7 Million USD | -2238.124% |
| HST Global, Inc. | 140.9 Thousand USD | -160948.777% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -20073.081% |
| Halberd Corporation | 74.84 Thousand USD | -303110.764% |
| Enzolytics Inc. | 2.17 Million USD | -10311.942% |
| Agentix Corp. | 1.37 Million USD | -16442.957% |
| Resverlogix Corp. | 12.71 Million USD | -1685.156% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -6116.029% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 85.202% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -21636.494% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -9335.976% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -14268.461% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -6564.623% |
| AVAX Technologies, Inc. | 7.31 Million USD | -3004.252% |
| Zenith Capital Corp. | 8.94 Million USD | -2437.504% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -1302517.531% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -9142.35% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -132213.173% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -11713.644% |
| Kadimastem Ltd | 2.41 Million USD | -9315.704% |
| Helix BioMedix, Inc. | 1.97 Million USD | -11407.357% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -124940.086% |
| LadRx Corporation | 3.81 Million USD | -5853.343% |
| Cell Source, Inc. | 4.32 Million USD | -5146.494% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -24472.446% |
| NovAccess Global Inc. | 2.46 Million USD | -9099.473% |
| Affymax, Inc. | 39.38 Million USD | -476.167% |
| Itoco Inc. | 919.14 Thousand USD | -24589.194% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -5254.102% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -20179.625% |
| Mobile Lads Corp. | 554.54 Thousand USD | -40821.583% |
| CytoDyn Inc. | 18.05 Million USD | -1156.667% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -901521.042% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -103012.987% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -15883.257% |
| SYBLEU INC | 160.87 Thousand USD | -140958.331% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -12393.889% |
| International Stem Cell Corporation | 5.27 Million USD | -4205.236% |
| Bioxytran, Inc. | 3.82 Million USD | -5840.321% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -430979.746% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -1115413.936% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -525.735% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -13925.278% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -30739.658% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -7194.407% |
| Neutra Corp. | 243.82 Thousand USD | -92971.967% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -1199.931% |
| PureTech Health plc | 144.59 Million USD | -56.939% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -1007.517% |
| IXICO plc | 4.7 Million USD | -4721.096% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -2479.618% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -92.724% |
| CSL Limited | 3.89 Billion USD | 94.171% |
| Cellectis S.A. | 97.32 Million USD | -133.178% |